Market Place
Sourcing Support
Surrozen Provides Q3 2024 Financial Results and Business Update
06 Nov 2024 //
GLOBENEWSWIRE
Surrozen to Present at Upcoming Healthcare Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Surrozen & TCGFB Announce Collaboration for IPF TGF-? Antibodies
04 Nov 2024 //
GLOBENEWSWIRE
The Column Group biotech taps Surrozen to target lung fibrosis
04 Nov 2024 //
FIERCE BIOTECH
Surrozen Earns $10M Milestone in Retinal Diseases Collaboration
24 Sep 2024 //
GLOBENEWSWIRE
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
12 Aug 2024 //
GLOBENEWSWIRE
Surrozen`s SWEETS Platform Enhances Wnt Signaling: eLife Study
12 Jun 2024 //
GLOBENEWSWIRE
Surrozen Presents SZN-043 Phase 1a Data At EASL 2024 For Liver Cirrhosis
10 Jun 2024 //
GLOBENEWSWIRE
Surrozen: Phase 1b Dosing For SZN-043 In Severe Alcoholic Hepatitis
04 Jun 2024 //
GLOBENEWSWIRE
Surrozen Data On Wnt Mimetics At ARVO Annual Meeting 2024
09 May 2024 //
GLOBENEWSWIRE
Surrozen Provides First Quarter 2024 Financial Results and Business Update
08 May 2024 //
GLOBENEWSWIRE
Surrozen Publishes `Respiratory Research` Demonstrating the Promise of a Wnt
03 Apr 2024 //
GLOBENEWSWIRE
Surrozen Announces up to $192.5 Million Private Placement
01 Apr 2024 //
GLOBENEWSWIRE
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
01 Apr 2024 //
GLOBENEWSWIRE
Surrozen Provides Corporate Update on Clinical Programs
18 Jan 2024 //
GLOBENEWSWIRE
Surrozen stops IBD program due to dose concerns and competition
18 Jan 2024 //
FIERCE BIOTECH
Surrozen Provides Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Surrozen culls 2 research programs as cash preservation persists
10 Aug 2023 //
FIERCE BIOTECH
Surrozen Provides Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Surrozen Publishes in Nature Demonstrating the Promise of a Fzd4 Wnt Antibody
05 Jun 2023 //
GLOBENEWSWIRE
Surrozen Provides 1Q 2023 Financial Results and Corporate and Pipeline Updates
10 May 2023 //
GLOBENEWSWIRE
Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt
05 Apr 2023 //
GLOBENEWSWIRE
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results
22 Mar 2023 //
GLOBENEWSWIRE
Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results
20 Mar 2023 //
GLOBENEWSWIRE
Surrozen Chooses TransPerfect’s Trial Interactive Platform for TMF Management
21 Feb 2023 //
BUSINESSWIRE
Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Surrozen halts trial as liver enzyme elevations crop up
15 Nov 2022 //
FIERCEBIOTECH
Surrozen Presents Data on Two Lead Therapeutic Candidates at (UEG)
10 Oct 2022 //
GLOBENEWSWIRE
Surrozen Announces Partnership with Boehringer to Develop Wnt Agonist SZN-413
07 Oct 2022 //
GLOBENEWSWIRE
Surrozen Publishes Study in Translational Vision Science and Technology SZN-413
26 Sep 2022 //
GLOBENEWSWIRE
Surrozen Initiates Dosing in PI Trial of SZN-043 for Severe Alcoholic Hepatitis
13 Jun 2022 //
GLOBENEWSWIRE
Surrozen Presents Data on Lead Therapeutic Candidates at DDW
24 May 2022 //
GLOBENEWSWIRE
Surrozen Initiates Dosing in PI Trial of SZN-1326 for Ulcerative Colitis
18 May 2022 //
GLOBENEWSWIRE
Surrozen Publishes Article in CMGH Demonstrating that SZN-1326
16 May 2022 //
GLOBENEWSWIRE
Surrozen Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
05 May 2022 //
GLOBENEWSWIRE
Surrozen Presents Data on Potential of SZN-413 for Diabetic Retinopathy at ARVO
02 May 2022 //
GLOBENEWSWIRE
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Surrozen: 2022 Milestones for Lead Program & Acceleration of Research Pipeline
10 Jan 2022 //
GLOBENEWSWIRE
Surrozen Presents Data Supporting Potential of SZN-043
15 Nov 2021 //
BIOSPACE
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021
15 Nov 2021 //
GLOBENEWSWIRE
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
15 Nov 2021 //
GLOBENEWSWIRE
Surrozen Presented Data Supporting Potential of SZN-1326
05 Oct 2021 //
GLOBENEWSWIRE
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326
09 Jul 2021 //
GLOBENEWSWIRE
Surrozen Presents Data at 2021 ILC for Wnt-Modulating Antibody SZN-043
25 Jun 2021 //
GLOBENEWSWIRE
Surrozen Presents Positive Data Supporting Potential of SZN-043
17 Jun 2021 //
GLOBENEWSWIRE
Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination
15 Apr 2021 //
BUSINESSWIRE
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using
15 Apr 2021 //
BUSINESSWIRE
